Niclas Axel Petri

Niclas Axel Petri is a notable inventor based in Copenhagen, Denmark. He has made significant contributions to the field of medical science, particularly in the treatment of inflammatory diseases. His innovative approach has led to the development of a selective IL-6-trans-signalling inhibitor, which has the potential to revolutionize treatment options for various conditions.

Latest Patents

Niclas holds a patent for "Methods for treatment of inflammatory disease or IL-6-mediated condition with gp130 protein." This patent describes a selective IL-6-trans-signalling inhibitor that can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can be safely administered to humans at various doses. Moreover, it lessens the deleterious effects associated with other IL-6 inhibitors, such as lowering neutrophil counts, platelet counts, and levels of C-reactive protein. He has 1 patent to his name.

Career Highlights

Niclas is currently associated with Ferring B.V., a company known for its commitment to advancing medical science. His work at Ferring has allowed him to focus on innovative treatments that address critical health issues. His dedication to research and development has positioned him as a key player in the field of inflammatory disease treatment.

Collaborations

Niclas collaborates with Ian Cottingham, a fellow innovator in the medical field. Their partnership exemplifies the importance of teamwork in advancing scientific research and developing effective treatments.

Conclusion

Niclas Axel Petri's contributions to the treatment of inflammatory diseases highlight his innovative spirit and commitment to improving patient outcomes. His work continues to inspire advancements in medical science and offers hope for those affected by IL-6-mediated conditions.

Profile summary based on public USPTO records.